Holen Sie sich die Stockscreener-App
1.99
10.56%
0.19
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MSN
Cabaletta Bio stock price target reiterated on strong clinical data By Investing.com - Investing.com India
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock - Investing.com Australia
Cabaletta Bio’s (CABA) Buy Rating Reaffirmed at HC Wainwright - Defense World
Analysts Offer Predictions for Cabaletta Bio FY2026 Earnings - Defense World
Cabaletta Bio Launches Public Offering Of Stock And Warrants - Nasdaq
Cabaletta Bio (CABA) Shares Drop 20% After Public Offering Annou - GuruFocus
Cabaletta Bio prices $100 million public offering of shares and warrants By Investing.com - Investing.com South Africa
Cabaletta reports positive clinical data for autoimmune cell therapy By Investing.com - Investing.com South Africa
Cabaletta Bio looks to raise $100M in stock sale to fund cell therapy development - The Business Journals
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wainwright & Co. | CABA Stock News - GuruFocus
Cabaletta Bio shares CAR-T results in three autoimmune conditions - Endpoints News
Cabaletta Bio Prices Securities Offering; Shares Fall - marketscreener.com
Cabaletta Bio stock tumbles after pricing $100 million public offering - Investing.com Australia
Cabaletta Bio Announces Pricing of Public Offering of Securities - GuruFocus
Cabaletta Bio prices $100 million public offering of shares and warrants - Investing.com
Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction - Seeking Alpha
Cantor Fitzgerald Predicts Cabaletta Bio FY2026 Earnings - MarketBeat
Cabaletta Bio announces public offering of common stock and warrants - Investing.com
Cabaletta Bio (CABA) Launches Public Offering with Warrants | CABA Stock News - GuruFocus
Cabaletta Bio (CABA) Showcases Promising Rese-cel Data at EULAR 2025 | CABA Stock News - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities | - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities - The Manila Times
Cabaletta Bio Announces Proposed Public Offering of Securities | CABA Stock News - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress | CABA Stock News - GuruFocus
Autoimmune Disease Pioneer Cabaletta Bio Announces Major Public Offering With Jefferies Leading - Stock Titan
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - The Manila Times
Cabaletta reports positive clinical data for autoimmune cell therapy - Investing.com
Breakthrough: New Autoimmune Therapy Achieves Drug-Free Remission in 94% of Trial Patients - Stock Titan
Cabaletta Bio Stockholders Approve Key Proposals - TipRanks
Squarepoint Ops LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Millennium Management LLC Has $1.16 Million Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Wellington Management Group LLP Grows Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
CrowdStrike Stock Drops on Cautious Outlook -- Is This a Buying Opportunity? - The Globe and Mail
Two Sigma Investments LP Has $1.71 Million Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Bank of America Corp DE Buys 67,787 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Down 40% This Year, Is UnitedHealth Group's Dividend in Danger? - The Globe and Mail
Millennium Management LLC Sells 1,217,300 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Two Sigma Investments LP Boosts Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Two Sigma Advisers LP Has $1.89 Million Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
BNP Paribas Financial Markets Acquires Shares of 51,952 Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Jefferies Global Healthcare Conference 2025 - MSN
Northern Trust Corp Sells 5,849 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Jefferies Global Healthcare Conference on June 4, 2025 - Nasdaq
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Cabaletta Bio Showcases First-Ever Curative Autoimmune Cell Therapies at Major Jefferies Conference - Stock Titan
D. E. Shaw & Co. Inc. Sells 17,359 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MSN
Point72 Asset Management L.P. Acquires 598,607 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Announces Quarterly Earnings Results - MarketBeat
Cantor Fitzgerald Predicts Weaker Earnings for Cabaletta Bio - MarketBeat
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):